GlassScriptPhysician profile
Shawn Allen
NPI 1083147441
$35,573.22
in general payments reported to CMS, 2019-2025
41 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $3,888 · 2024: $1,768 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $6,791 · Consulting Fee: $6,138 · Travel and Lodging: $6,108 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,280.00 |
| Food and Beverage | $6,791.28 |
| Consulting Fee | $6,137.50 |
| Travel and Lodging | $6,108.21 |
| Education | $133.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20,892.96 | 2025 | |
| Argenx US, INC. | $8,186.82 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Abbott Laboratories | $1,434.69 | 2023-2024 | Infinity, Proclaim |
| Abbvie INC. | $1,077.27 | 2022-2025 | Ubrelvy, Botox, Qulipta |
| Boston Scientific Corporation | $595.41 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Watchman Flx |
| Biogen, INC. | $567.13 | 2023-2025 | Vumerity, Tysabri, Tysabri |
| Novartis Pharmaceuticals Corporation | $394.02 | 2023-2025 | |
| Pfizer INC. | $339.79 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $268.81 | 2023-2025 | Purified Cortrophin Gel |
| Emd Serono, INC. | $235.21 | 2023-2024 | Mavenclad |
| Lundbeck LLC | $230.86 | 2022-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $149.88 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $146.73 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| E.R. Squibb & Sons, L.L.C. | $114.92 | 2023 | Zeposia |
| Ucb, INC. | $95.87 | 2024-2025 | Zilbrysq, Rystiggo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $94.03 | 2023-2025 | Nuplazid |
| Averitas Pharma INC. | $91.51 | 2023-2024 | Qutenza |
| Neurocrine Biosciences, INC. | $77.78 | 2023-2025 | Ingrezza |
| Celgene Corporation | $65.93 | 2023-2025 | Zeposia |
| Lilly USA, LLC | $60.34 | 2024-2025 | Kisunla, Amyvid |
| Grifols USA, LLC | $49.42 | 2024-2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $40.22 | 2023-2024 | |
| Amgen INC. | $33.35 | 2025 | Uplizna |
| Tg Therapeutics, INC. | $32.22 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.48 | 2025 | |
| Eisai INC. | $20.61 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.82 | 2024 | Hyqvia |
| Spr Therapeutics, INC | $19.39 | 2024 | Sprint Pns System |
| Merz Pharmaceuticals, LLC | $18.48 | 2025 | Inbrija, Xeomin |
| Kedrion Biopharma, INC. | $18.09 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Recordati_rare_diseases_inc. | $18.05 | 2024 | Signifor Lar, Isturisa |
| Csl Behring | $17.03 | 2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $16.96 | 2025 | Rexulti |
| Corcept Therapeutics | $16.56 | 2022 | |
| Cycle Pharmaceuticals INC | $16.54 | 2025 | Bafiertam |
| Amneal Pharmaceuticals LLC | $16.21 | 2024 | Rytary |
| Banner Life Sciences, LLC | $15.35 | 2024 | |
| Mallinckrodt Hospital Products INC. | $14.99 | 2025 | Acthar |
| Insightec,INC | $10.77 | 2024 | Exablate |
| Janssen Scientific Affairs, LLC | $8.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.